The 4N Cell Cycle Delay in Fanconi Anemia Reflects Growth Arrest in Late S Phase
Overview
Affiliations
Fanconi anemia (FA) is a human genetic disorder characterized by hypersensitivity to DNA crosslinking agents. Its cellular phenotypes include increased chromosome breakage and a marked cell-cycle delay with 4N DNA content after introduction of interstrand DNA crosslinks (ICL). To further understand the nature of this delay previously described as a G2/M arrest, we introduced ICL specifically during G2 and monitored the cells for passage into mitosis. Our results showed that, even at the highest doses, postreplication ICL produced neither G2/M arrest nor chromosome breakage in FA-A or FA-C cells. This suggests that, similar to wild-type cells, DNA replication is required to trigger both responses. Therefore, the 4N cell DNA content observed in FA cells after ICL treatment also represents incomplete DNA replication and arrest in late S phase. FA fibroblasts from complementation groups A and C were able to recover from the ICL-induced cell-cycle arrest, but took approximately 3 times longer than controls. These results indicate that the FA pathway is required for the efficient resolution of ICL-induced S-phase arrest.
A CRISPR-Cas9 screen identifies EXO1 as a formaldehyde resistance gene.
Gao Y, Guitton-Sert L, Dessapt J, Coulombe Y, Rodrigue A, Milano L Nat Commun. 2023; 14(1):381.
PMID: 36693839 PMC: 9873647. DOI: 10.1038/s41467-023-35802-y.
PFKFB3 Inhibition Sensitizes DNA Crosslinking Chemotherapies by Suppressing Fanconi Anemia Repair.
Ninou A, Lehto J, Chioureas D, Stigsdotter H, Schelzig K, Akerlund E Cancers (Basel). 2021; 13(14).
PMID: 34298817 PMC: 8306909. DOI: 10.3390/cancers13143604.
Targeting CX3CR1 Suppresses the Fanconi Anemia DNA Repair Pathway and Synergizes with Platinum.
Lehto J, Ninou A, Chioureas D, Jonkers J, Gustafsson N Cancers (Basel). 2021; 13(6).
PMID: 33810010 PMC: 8004634. DOI: 10.3390/cancers13061442.
Verhagen C, Vossen D, Borgmann K, Hageman F, Grenman R, Verwijs-Janssen M Oncotarget. 2018; 9(26):18198-18213.
PMID: 29719599 PMC: 5915066. DOI: 10.18632/oncotarget.24797.
SNM1B/Apollo in the DNA damage response and telomere maintenance.
Schmiester M, Demuth I Oncotarget. 2017; 8(29):48398-48409.
PMID: 28430596 PMC: 5564657. DOI: 10.18632/oncotarget.16864.